Anti-Cd33 Car-Nk Cells
Acute Myeloid Leukemia By FAB Classification
Explore 16 assets in Acute Myeloid Leukemia By FAB Classification →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02944162CT.gov CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia By FAB Classification
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Cd33 Car-Nk Cells (this asset) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | P1/2 | CCC · 48 |
| Daunomycin | Wake Forest University Health Sciences | P3 | BBB |
| Idarubicin | University of Nebraska | P3 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P3 | BB |
| Mercaptopurine Anhydrous | Roswell Park Cancer Institute | P3 | B |
| Valspodar | National Cancer Institute (NCI) | P3 | B |
| Azacitidine | guomei | P2 | B |
| Caspofungin | Children's Oncology Group | P3 | B |
| Augmerosen | National Cancer Institute (NCI) | P3 | B |
+41 more in the Acute Myeloid Leukemia By FAB Classification cohort
Other indications for Anti-Cd33 Car-Nk Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloblastic Leukemia With Maturation | — | P1/2 | CCC · 48 |
| Acute Myeloid Leukemia | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DaunomycinWake Forest University Health SciencesBBB
- IdarubicinUniversity of NebraskaBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- Mercaptopurine AnhydrousRoswell Park Cancer InstituteB
- ValspodarNational Cancer Institute (NCI)B
Citation
Floatz Terminal. Anti-Cd33 Car-Nk Cells in Acute Myeloid Leukemia By FAB Classification. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-cd33-car-nk-cells-acute-myeloid-leukemia-by-fab-classification
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →